Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02449837 · ClinicalTrials.gov registry record

Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy

A clinical trial of Circulating Tumor Cells, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
162
Enrollment target
1
Study location

NCT02449837 is a study of Circulating Tumor Cells that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 162 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02449837, a study of Circulating Tumor Cells, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
162 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the level of Circulating Tumor Cells (CTCs) in cancer patients before and after undergoing treatment regimens where the primary treatment modality is radiation therapy (XRT). Specifically, there is interest in the change in CTCs pre- and post- XRT, both in absolute and relative terms.

Conditions Studied

Interventions

  • OTHER Blood draw

Study Locations (1)

North Carolina

  • University of North Carolina at Chapel Hill, Department of Radiation Oncology - Chapel Hill

Trial Details

FieldValue
Enrollment Target 162 participants
Start Date 2014-05
Est. Completion 2022-02-20

What the Registry Record Tells You About NCT02449837

The ClinicalTrials.gov registry entry for NCT02449837 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Circulating Tumor Cells appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.

NCT02449837 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT02449837 about?

NCT02449837 is a clinical study titled "Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy". The purpose of this study is to investigate the level of Circulating Tumor Cells (CTCs) in cancer patients before and after undergoing treatment regimens where the primary treatment modality is radiation therapy (XRT). Specifically, there is interest in the change in CTCs pre- and post- XRT, both in...

What is the current status of trial NCT02449837?

This trial is currently completed. The enrollment target is 162 participants. The study started on 2014-05. Estimated completion is 2022-02-20.

What conditions does trial NCT02449837 study?

This clinical trial studies the following conditions: Circulating Tumor Cells.

What interventions are being tested in trial NCT02449837?

The interventions under investigation include: Blood draw (OTHER).

Who is sponsoring clinical trial NCT02449837?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02449837 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Circulating Tumor Cells

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.